OC.02.5 EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS. (1st October 2020) - Privitera, G.